GlobeNewswire
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
📈
AI Sentiment
Highly Positive
8/10
- Home
- OGEN
OGEN
Oragenics Inc.
as of 03-17-2026 10:48am EST
$0.76
$0.04
-4.50%
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SARASOTA |
| Market Cap: | 3.6M | IPO Year: | 2010 |
| Target Price: | N/A | AVG Volume (30 days): | 537.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.56 | EPS Growth: | -185.00 |
| 52 Week Low/High: | $0.11 - $9.16 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.17 | Index: | N/A |
| Free Cash Flow: | -9373906.0 | FCF Growth: | N/A |
AI-Powered OGEN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 16 hours ago
AI Recommendation
hold
Model Accuracy: 76.10%
76.10%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Oragenics Inc. News
OGEN Breaking Stock News: Dive into OGEN Ticker-Specific Updates for Smart Investing
GlobeNewswire
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
📈
AI Sentiment
Highly Positive
9/10
Compare OGEN vs Leading Stocks
See how OGEN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "OGEN Oragenics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.